HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.

Abstract
Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual patient disease triggers and response to therapy. Several asthma phenotypes have now been identified, each defined by a unique interaction between genetic and environmental factors, including inflammatory, clinical and trigger-related phenotypes. Endotypes further describe the functional or pathophysiologic mechanisms underlying the patient's disease. type 2-driven asthma is an emerging nomenclature for a common subtype of asthma and is characterized by the release of signature cytokines IL-4, IL-5 and IL-13 from cells of both the innate and adaptive immune systems. A number of well-recognized biomarkers have been linked to mechanisms involved in type 2 airway inflammation, including fractional exhaled nitric oxide, serum IgE, periostin, and blood and sputum eosinophils. These type 2 cytokines are targets for pharmaceutical intervention, and a number of therapeutic options are under clinical investigation for the management of patients with uncontrolled severe asthma. Anticipating and understanding the heterogeneity of asthma and subsequent improved characterization of different phenotypes and endotypes must guide the selection of treatment to meet individual patients' needs.
AuthorsD Robinson, M Humbert, R Buhl, A A Cruz, H Inoue, S Korom, N A Hanania, P Nair
JournalClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (Clin Exp Allergy) Vol. 47 Issue 2 Pg. 161-175 (Feb 2017) ISSN: 1365-2222 [Electronic] England
PMID28036144 (Publication Type: Journal Article, Review)
Copyright© 2017 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd.
Chemical References
  • Biomarkers
  • Cytokines
  • Inflammation Mediators
Topics
  • Animals
  • Asthma (etiology, metabolism, pathology, therapy)
  • Biomarkers
  • Cytokines (metabolism)
  • Humans
  • Inflammation (immunology, metabolism, pathology, therapy)
  • Inflammation Mediators (metabolism)
  • Signal Transduction
  • T-Lymphocyte Subsets (immunology, metabolism)
  • Th2 Cells (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: